IL129949A - Use of minesulide in the preparation of pharmaceutical compositions for treating neurodegenerative conditions - Google Patents

Use of minesulide in the preparation of pharmaceutical compositions for treating neurodegenerative conditions

Info

Publication number
IL129949A
IL129949A IL12994997A IL12994997A IL129949A IL 129949 A IL129949 A IL 129949A IL 12994997 A IL12994997 A IL 12994997A IL 12994997 A IL12994997 A IL 12994997A IL 129949 A IL129949 A IL 129949A
Authority
IL
Israel
Prior art keywords
neurodegenerative conditions
minesulide
preparation
pharmaceutical compositions
treating neurodegenerative
Prior art date
Application number
IL12994997A
Other languages
English (en)
Other versions
IL129949A0 (en
Original Assignee
Mount Sin I School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sin I School Of Medicine filed Critical Mount Sin I School Of Medicine
Priority to IL14487197A priority Critical patent/IL144871A/en
Publication of IL129949A0 publication Critical patent/IL129949A0/xx
Publication of IL129949A publication Critical patent/IL129949A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IL12994997A 1996-11-21 1997-11-19 Use of minesulide in the preparation of pharmaceutical compositions for treating neurodegenerative conditions IL129949A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL14487197A IL144871A (en) 1996-11-21 1997-11-19 Transgenic mouse carrying a gene encoding the human cyclooxygenase-2 gene and a neuronal cell culture prepared from same transgenic mouse

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3333296P 1996-11-21 1996-11-21
US08/831,402 US5985930A (en) 1996-11-21 1997-04-01 Treatment of neurodegenerative conditions with nimesulide
PCT/US1997/021484 WO1998022104A2 (en) 1996-11-21 1997-11-19 Treatment of neurodegenerative conditions with nimesulide

Publications (2)

Publication Number Publication Date
IL129949A0 IL129949A0 (en) 2000-02-29
IL129949A true IL129949A (en) 2003-05-29

Family

ID=26709565

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12994997A IL129949A (en) 1996-11-21 1997-11-19 Use of minesulide in the preparation of pharmaceutical compositions for treating neurodegenerative conditions

Country Status (18)

Country Link
US (3) US5985930A (da)
EP (1) EP0956009B9 (da)
JP (1) JP2001505206A (da)
KR (1) KR20000069061A (da)
AT (1) ATE212546T1 (da)
AU (1) AU725141B2 (da)
BR (1) BR9714303A (da)
CA (1) CA2272249A1 (da)
DE (1) DE69710224T2 (da)
DK (1) DK0956009T3 (da)
ES (1) ES2172822T3 (da)
IL (1) IL129949A (da)
NO (1) NO992374L (da)
NZ (1) NZ335726A (da)
PT (1) PT956009E (da)
SK (1) SK284334B6 (da)
TR (1) TR199901120T2 (da)
WO (1) WO1998022104A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO2000034521A1 (en) * 1998-12-08 2000-06-15 Boston Probes, Inc. Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices
NZ514453A (en) * 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
EP1235851B1 (en) 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
JP2004517892A (ja) 2000-12-13 2004-06-17 ワイス β−アミロイド産生の複素環スルホンアミド阻害剤
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
US20040063752A1 (en) * 2002-05-31 2004-04-01 Pharmacia Corporation Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX-2) inhibitor(s)
AU2003237988A1 (en) * 2002-06-13 2003-12-31 Mount Sinai School Of Medicine Of New York University Inhibiting progressive cognitive impairment
US20060041022A1 (en) * 2002-11-06 2006-02-23 Pasinetti Giulio M Treatment of amyotrophic lateral sclerosis with nimesulide
AU2003218345A1 (en) * 2002-11-06 2004-06-03 Mount Sinai School Of Medicine Treatment of amyotrophic lateral sclerosis with nimesulide
KR20060002908A (ko) 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
WO2010107702A1 (en) * 2009-03-16 2010-09-23 Ipintl, Llc Treating alzheimer's disease and osteoporosis and reducing aging
US8324450B2 (en) 2009-06-02 2012-12-04 Academia Sinica Non-human animal model for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U)
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
ES2724803T3 (es) 2011-12-16 2019-09-16 Univ Leland Stanford Junior Polipéptidos opsinas y métodos de utilización de los mismos
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
JP6586075B2 (ja) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
JP6621747B2 (ja) 2013-08-14 2019-12-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛を制御するための組成物及び方法
CN106413811A (zh) 2013-10-22 2017-02-15 夏尔人类遗传性治疗公司 精氨基琥珀酸合成酶缺乏症的mrna疗法
CN106459138A (zh) 2014-03-28 2017-02-22 斯坦福大学托管董事会 工程化的光激活阴离子通道蛋白及其使用方法
US9850269B2 (en) * 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
WO2016085876A1 (en) 2014-11-25 2016-06-02 The Broad Institute Inc. Clonal haematopoiesis
EP3224381B1 (en) 2014-11-25 2019-09-04 The Brigham and Women's Hospital, Inc. Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease
US10667691B2 (en) 2015-08-31 2020-06-02 The Board Of Trustees Of The Leland Stanford Junior University Compressed sensing high resolution functional magnetic resonance imaging
KR102893860B1 (ko) * 2015-12-09 2025-12-03 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 기능적 뇌 회로 분석법
WO2017136285A1 (en) 2016-02-01 2017-08-10 The Board Of Trustees Of The Leland Stanford Junior University Method and systems for analyzing functional imaging data
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
KR102950141B1 (ko) 2018-08-24 2026-04-07 트랜슬레이트 바이오 인코포레이티드 전령 rna의 정제 방법
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Type II stable opsins and methods of using them
EP4031662A1 (en) 2019-09-20 2022-07-27 Translate Bio, Inc. Mrna encoding engineered cftr
WO2025189030A1 (en) 2024-03-07 2025-09-12 Stellaromics, Inc. Methods and systems for volumetric imaging

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3403096A (en) * 1963-10-02 1968-09-24 Ceskoslovenska Akademie Ved Method and device for separation of a suspension
US4966692A (en) * 1989-05-05 1990-10-30 Flint & Walling, Inc. Filtration system having flow control means and tank adapter with selective venting
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JPH10506615A (ja) * 1994-07-27 1998-06-30 ザ、プロクター、エンド、ギャンブル、カンパニー 抗炎症剤として有用なジヒドロベンゾフラン及び関連化合物
US5684002A (en) * 1994-09-07 1997-11-04 The Procter & Gamble Company Dihydorbenzofuran and related compounds useful as anti-inflammatory agents
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5510361A (en) * 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
CA2164559A1 (en) * 1994-12-09 1996-06-10 Chun-Sing Li 5-methanesulfonamido-6-(2-pyridylthio)-1-indanones as inhibitors of cyclooxygenase-2
WO1996019469A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors
AU4479096A (en) * 1995-01-31 1996-08-21 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
BR9607035A (pt) * 1995-02-13 1997-11-04 Searle & Co Isoxazois substituidos para o tratamento de inflamação
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
ITMI962356A1 (it) * 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide

Also Published As

Publication number Publication date
US20020162130A1 (en) 2002-10-31
NO992374L (no) 1999-07-21
DK0956009T3 (da) 2002-05-21
SK284334B6 (sk) 2005-02-04
ATE212546T1 (de) 2002-02-15
AU725141B2 (en) 2000-10-05
AU5361298A (en) 1998-06-10
NZ335726A (en) 2000-10-27
DE69710224D1 (de) 2002-03-14
US7226948B2 (en) 2007-06-05
NO992374D0 (no) 1999-05-18
EP0956009B9 (en) 2002-12-11
PT956009E (pt) 2002-07-31
EP0956009A1 (en) 1999-11-17
SK67199A3 (en) 2001-01-18
JP2001505206A (ja) 2001-04-17
US6649811B2 (en) 2003-11-18
CA2272249A1 (en) 1998-05-28
TR199901120T2 (xx) 1999-07-21
ES2172822T3 (es) 2002-10-01
WO1998022104A3 (en) 1998-10-08
WO1998022104A2 (en) 1998-05-28
US20060059576A1 (en) 2006-03-16
DE69710224T2 (de) 2002-10-02
BR9714303A (pt) 2000-04-25
IL129949A0 (en) 2000-02-29
KR20000069061A (ko) 2000-11-25
EP0956009B1 (en) 2002-01-30
US5985930A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
IL129949A (en) Use of minesulide in the preparation of pharmaceutical compositions for treating neurodegenerative conditions
MY111188A (en) Improvements in or relating to benzothiophenes.
IL131349A0 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
PL345030A1 (en) Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome
RU93048466A (ru) Применение бензотиофенов для профилактики и лечения остеопороза и фармацевтическая композиция на их основе
WO1999015167A3 (en) Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer
WO2003051313A3 (en) Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
WO1997047296A3 (en) Compositions comprising vanadium compounds for use in the treatment of proliferative disorders and arthropathies
IL140159A0 (en) Neuroprotective composition for the prevention and/or treatment of nervous and behavioral alterations due to anxiety states or depression
IL117874A0 (en) Pharmaceutical compositions for inhibiting the growth of viruses and cancers
WO2003061566A3 (en) Anti-cancer combination and use thereof
AU5314900A (en) Compositions and methods for inhibiting cell death
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
HU9501146D0 (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
WO1998036730A3 (de) Zubereitungen für die behandlung von rosacea
AU4830097A (en) Use of an extract of Cimicifuga
AU1509999A (en) Herbal drug composition for the prevention and treatment of dementia
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
FI961380A7 (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitam iseksi
BR9707844A (pt) Combinação de desidroepiandrosterona e inibidores de aromatase e emprego desta combinação para a preparação de um medicamento para o tratamento de uma deficiência de androgênio relativa e absoluta no homem
AU7941294A (en) Composition for the treatment or prevention of herpes

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees